Journal of Thrombosis and Thrombolysis · 2018 · 15 citations · 11 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical EpidemiologyClinical PharmacologyAnticoagulant ManagementAnticoagulant TherapyAnticoagulation ManagementAnticoagulation TherapyAtrial FibrillationThrombosisAlcohol Consumption PatternsAtrial Fibrillation ComplicationsAtrial Fibrillation Risk AssessmentIndividual Therapeutic RangePopulation Therapeutic RangeTherapeutic AnticoagulationTherapeutic Dose RangeTime In Therapeutic Range
Warfarin is well studied in patients with non-valvular atrial fibrillation (AF). It has low complication rates for patients achieving individual Time in Therapeutic Range (iTTR) > 70%. The risk scores SAMe-TT2R2 and PROSPER are designed to predict future TTR, but are derived from a heterogeneous population with generally low iTTR. The aim of this study was to evaluate predictors for high and low iTTR in an AF population in Sweden, where there is a generally good anticoagulation control. A retrospective register study based on Swedish warfarin dosing system AuriculA, including 28,011 AF patients starting treatment during 1 January 2006 to 31 December 2011. Complications and risk factors were analysed and related to iTTR. Mean age was 73.7 (SD ± 9.5) years, with 42.0% women. Mean CHA2DS2-VASc score (SD) was 3.6 (± 1.7). For patients with iTTR < 60% there were over three times higher prevalence of excessive alcohol consumption than for patients with iTTR > 70% (3.7% vs. 1.1%). Previous stroke were more prevalent for patients with high than low iTTR (17.1% vs. 20.3%). Concomitant comorbidities were associated with increased risk of poor iTTR. In Swedish AF patients, excessive alcohol use is clearly associated with iTTR below 60%. Patients with previous stroke are more likely to get iTTR above 70%, unlike those with concomitant disorders who more often have poor anticoagulation control. The SAMe-TT2R2-score cannot be applied in Sweden.
11
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
F.R. Rosendaal, Suzanne C. Cannegieter, F.J.M. van der Meer et al. · Thrombosis and Haemostasis · 1993 · 2.1K citations · Full text
Lars Wallentin, Salim Yusuf, Michael D. Ezekowitz et al. · The Lancet · 2010 · 1K citations
Medicine, Cardiology, Pharmacology +15